APP and Alzheimer disease: The CRISPR/Cas9-based genome-editing framework was used for transduction human iPSCs with heterozygous and homozygous dominant early onset AD-causing mutations in APP [APP (Swe)] and PSEN1 [PSEN1 (M146V)].